THIO and Cadonilimab in Resectable Hepatocellular Carcinoma

Part of paid clinical trials in Dallas, Texas.

Sponsor
University of Texas Southwestern Medical Center
Study ID
NCT07446257
Phase
EARLY_PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Resectable Hepatocellular Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ateganosine — DRUG
    ateganosine: 180 mg IV D1, D2, D3 of 21-day cycle
  • Cadonilimab — DRUG
    cadonilimab: 10 mg/kg IV D5 of 21-day cycle

Study Details

The goal of this clinical study is to find out if cadonilimab or ateganosine plus cadonilimab is effective and safe in treating resectable hepatocellular carcinoma (HCC).

Key Dates

Start date
May 1, 2026
Status verified
Feb 2026
Primary completion
May 1, 2030
Completion
May 1, 2031

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A: Ateganocine + Cadonilimab
    Ateganosine: 60 mg/day (180 mg/cycle) IV over 30 minutes±5 minutes Cadonilimab: 10 mg/kg IV over 60 minutes±5 minutes
  • Experimental: Arm B: Ateganocine
    Ateganosine: 60 mg/day (180 mg/cycle) IV over 30 minutes±5 minutes
  • Experimental: Arm C: Cadonilimab
    Cadonilimab: 10 mg/kg IV over 60 minutes±5 minutes

Primary Outcome Measure

Incidence of treatment-related delay of surgical resection >28 days from expected surgery date. [ Time Frame: 28 days after the expected surgery date (day 5 of cycle 3 for all treatment arms) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Texas Southwestern Medical CenterDallasTexas75390
Carrie Manwaring
[email protected]
214-648-7097
David Hsieh, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Dallas, TX

By research site
University of Texas Southwestern Medical Center· Dallas, TX

Related Studies